Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter (EVEREST-I)
Evaluation of Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter in the Treatment of Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Sponsor: Urotronic Inc.
A PHASE2 clinical study on Benign Prostatic Hyperplasia and Benign Prostatic Hypertrophy, this trial is completed. The trial is conducted by Urotronic Inc. and has accumulated 15 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Urotronic Inc.
For direct contact, visit the study record on ClinicalTrials.gov .